PET Pharm
吉晟生技股份有限公司
PET Pharm is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is 18F BPA (Phase 1/2 trial authorized, Companion diagnostic imaging for BNCT), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| 18F BPA | — | Phase 1/2 trial authorized | Companion diagnostic imaging for BNCT | Taiwan | 2026-04-30 | Company disclosure |
| 161Tb-PSMA I&T | — | Academic clinical trial authorized | Prostate cancer | Taiwan | 2026-04-30 | Company disclosure |
| 177Lu-PSMA I&T | — | Special manufacturing authorization; clinical supply | Prostate cancer | Taiwan | 2026-04-30 | Company disclosure |
Key events
No verified events in the past twelve months.